{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:03Z","timestamp":1787009043243,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"University of Washington School of Pharmacy Faculty Innovation Fund"},{"name":"University of Washington Royalty Research Fund","award":["A128444"],"award-info":[{"award-number":["A128444"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infection Diseases","doi-asserted-by":"crossref","award":["R21AI132994"],"award-info":[{"award-number":["R21AI132994"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infection Diseases","doi-asserted-by":"crossref","award":["R01AI136979"],"award-info":[{"award-number":["R01AI136979"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SINGH19R0"],"award-info":[{"award-number":["SINGH19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glycopeptides (GPs), lipopeptides (LPs) and lipoglycopeptides (LGPs) are related antimicrobials important for the management of invasive MRSA infections. Cross-resistance among these antibiotics in MRSA is well documented, as is the observation that susceptibility of MRSA to \u03b2-lactams increases as susceptibility to GPs and LPs decreases (i.e. the seesaw effect). Efforts to understand the relationship between GP\/LP\/LGP cross-resistance and the seesaw effect have focused on the PBPs, but the role of lipid metabolism has not been investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Since the cell membrane is structurally and metabolically integrated with the cell wall and anchors associated proteins, including PBPs, we examined the relationship between membrane lipid composition and the phenomena of cross-resistance among GPs\/LPs\/LGPs and the \u03b2-lactam seesaw effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We selected for daptomycin, vancomycin and dalbavancin resistance using the USA300 strain JE2 and evaluated the resulting mutants by WGS, MS-based lipidomics and antimicrobial susceptibility testing to assess the relationship between membrane composition, cross-resistance, and the seesaw effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed cross-resistance to GPs\/LPs\/LGPs among the selected strains and the seesaw effect against various \u03b2-lactams, depending on the PBP targets of the particular \u03b2-lactam. We found that modification of membrane composition occurs not only in daptomycin-selected strains, but also vancomycin- and dalbavancin-selected strains. Significantly, we observed that the abundance of most phosphatidylglycerols positively correlates with MICs of GPs\/LPs\/LGPs and negatively correlates with the MICs of \u03b2-lactams.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These studies demonstrate a major association between membrane remodelling, cross-resistance and the seesaw effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz562","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T15:10:17Z","timestamp":1576854617000},"page":"1182-1186","source":"Crossref","is-referenced-by-count":45,"title":["Occurrence of cross-resistance and \u03b2-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels"],"prefix":"10.1093","volume":"75","author":[{"given":"Kelly M","family":"Hines","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel K","family":"Ashford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Waalkes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsi","family":"Penewit","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Salipante","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-4098","authenticated-orcid":false,"given":"Brian J","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-5200","authenticated-orcid":false,"given":"Libin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"2021020815061448800_dkz562-B1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2021020815061448800_dkz562-B2","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","article-title":"Observation of \u201cseesaw effect\u201d with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains","volume":"3","author":"Barber","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2021020815061448800_dkz562-B4","doi-asserted-by":"crossref","first-page":"e1002359.","DOI":"10.1371\/journal.ppat.1002359","article-title":"Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR","volume":"7","author":"Howden","year":"2011","journal-title":"PLoS Pathog"},{"key":"2021020815061448800_dkz562-B5","doi-asserted-by":"crossref","first-page":"e1002505.","DOI":"10.1371\/journal.ppat.1002505","article-title":"Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300","volume":"8","author":"Gardete","year":"2012","journal-title":"PLoS Pathog"},{"key":"2021020815061448800_dkz562-B6","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1128\/AAC.00970-15","article-title":"Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-resistant Staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides","volume":"59","author":"Bayer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.00719-07","article-title":"Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding","volume":"52","author":"Jones","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.02182-12","article-title":"Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus","volume":"57","author":"Mishra","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B9","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2021020815061448800_dkz562-B10","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/AAC.00487-10","article-title":"Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the \u201cseesaw effect\u201d)","volume":"54","author":"Yang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B11","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.02308-12","article-title":"Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model: exploring the \u201cseesaw effect\u201d","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B12","doi-asserted-by":"crossref","first-page":"e01634","DOI":"10.1128\/AAC.01634-16","article-title":"Molecular bases determining daptomycin resistance-mediated resensitization to \u03b2-lactams (seesaw effect) in methicillin-resistant Staphylococcus aureus","volume":"61","author":"Renzoni","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B13","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/AAC.45.11.3070-3075.2001","article-title":"Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus","volume":"45","author":"Finan","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.47.3.1028-1036.2003","article-title":"Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin","volume":"47","author":"Boyle-Vavra","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam-daptomycin synergy","volume":"60","author":"Berti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020815061448800_dkz562-B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-micro-091213-112949","article-title":"Lipoteichoic acid synthesis and function in gram-positive bacteria","volume":"68","author":"Percy","year":"2014","journal-title":"Annu Rev Microbiol"},{"key":"2021020815061448800_dkz562-B17","doi-asserted-by":"crossref","first-page":"e00492","DOI":"10.1128\/mSphere.00492-17","article-title":"Characterization of the mechanisms of daptomycin resistance among Gram-positive bacterial pathogens by multidimensional lipidomics","volume":"2","author":"Hines","year":"2017","journal-title":"mSphere"},{"key":"2021020815061448800_dkz562-B18","year":"2019"},{"key":"2021020815061448800_dkz562-B19","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/JCM.03385-14","article-title":"Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology","volume":"53","author":"Salipante","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2021020815061448800_dkz562-B20","doi-asserted-by":"crossref","first-page":"e00517","DOI":"10.1128\/mBio.00517-17","article-title":"Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa","volume":"8","author":"Jorth","year":"2017","journal-title":"mBio"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/5\/1182\/36214020\/dkz562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/5\/1182\/36214020\/dkz562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:08:54Z","timestamp":1612818534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/5\/1182\/5722227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,4]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz562","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/671438","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,4]]}}}